Literature DB >> 25071115

Host antitumor immunity plays a role in the survival of patients with newly diagnosed triple-negative breast cancer.

Sherene Loi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25071115     DOI： 10.1200/JCO.2014.56.7677

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  24 in total

1.  Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.

Authors:  Zuzana Kos; Elvire Roblin; Rim S Kim; Stefan Michiels; Brandon D Gallas; Weijie Chen; Koen K van de Vijver; Shom Goel; Sylvia Adams; Sandra Demaria; Giuseppe Viale; Torsten O Nielsen; Sunil S Badve; W Fraser Symmans; Christos Sotiriou; David L Rimm; Stephen Hewitt; Carsten Denkert; Sibylle Loibl; Stephen J Luen; John M S Bartlett; Peter Savas; Giancarlo Pruneri; Deborah A Dillon; Maggie Chon U Cheang; Andrew Tutt; Jacqueline A Hall; Marleen Kok; Hugo M Horlings; Anant Madabhushi; Jeroen van der Laak; Francesco Ciompi; Anne-Vibeke Laenkholm; Enrique Bellolio; Tina Gruosso; Stephen B Fox; Juan Carlos Araya; Giuseppe Floris; Jan Hudeček; Leonie Voorwerk; Andrew H Beck; Jen Kerner; Denis Larsimont; Sabine Declercq; Gert Van den Eynden; Lajos Pusztai; Anna Ehinger; Wentao Yang; Khalid AbdulJabbar; Yinyin Yuan; Rajendra Singh; Crispin Hiley; Maise Al Bakir; Alexander J Lazar; Stephen Naber; Stephan Wienert; Miluska Castillo; Giuseppe Curigliano; Maria-Vittoria Dieci; Fabrice André; Charles Swanton; Jorge Reis-Filho; Joseph Sparano; Eva Balslev; I-Chun Chen; Elisabeth Ida Specht Stovgaard; Katherine Pogue-Geile; Kim R M Blenman; Frédérique Penault-Llorca; Stuart Schnitt; Sunil R Lakhani; Anne Vincent-Salomon; Federico Rojo; Jeremy P Braybrooke; Matthew G Hanna; M Teresa Soler-Monsó; Daniel Bethmann; Carlos A Castaneda; Karen Willard-Gallo; Ashish Sharma; Huang-Chun Lien; Susan Fineberg; Jeppe Thagaard; Laura Comerma; Paula Gonzalez-Ericsson; Edi Brogi; Sherene Loi; Joel Saltz; Frederick Klaushen; Lee Cooper; Mohamed Amgad; David A Moore; Roberto Salgado
Journal:  NPJ Breast Cancer       Date:  2020-05-12

Review 2.  Towards tumor immunodiagnostics.

Authors:  Helen Kourea; Vassiliki Kotoula
Journal:  Ann Transl Med       Date:  2016-07

3.  Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes.

Authors:  Andres Forero; Yufeng Li; Dongquan Chen; William E Grizzle; Katherine L Updike; Natalie D Merz; Erinn Downs-Kelly; Todd C Burwell; Christos Vaklavas; Donald J Buchsbaum; Richard M Myers; Albert F LoBuglio; Katherine E Varley
Journal:  Cancer Immunol Res       Date:  2016-03-15       Impact factor: 11.151

4.  Loss of Core 1-derived O-Glycans Decreases Breast Cancer Development in Mice.

Authors:  Kai Song; Brett H Herzog; Jianxin Fu; Minjia Sheng; Kirk Bergstrom; J Michael McDaniel; Yuji Kondo; Samuel McGee; Xiaofeng Cai; Ping Li; Hong Chen; Lijun Xia
Journal:  J Biol Chem       Date:  2015-06-29       Impact factor: 5.157

5.  Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.

Authors:  Stephen J Luen; Roberto Salgado; Stephen Fox; Peter Savas; Jennifer Eng-Wong; Emma Clark; Astrid Kiermaier; Sandra M Swain; Jose Baselga; Stefan Michiels; Sherene Loi
Journal:  Lancet Oncol       Date:  2016-12-07       Impact factor: 41.316

6.  Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer.

Authors:  Shivaani Kummar; James L Wade; Amit M Oza; Daniel Sullivan; Alice P Chen; David R Gandara; Jiuping Ji; Robert J Kinders; Lihua Wang; Deborah Allen; Geraldine O'Sullivan Coyne; Seth M Steinberg; James H Doroshow
Journal:  Invest New Drugs       Date:  2016-03-21       Impact factor: 3.850

Review 7.  Clinical relevance of host immunity in breast cancer: from TILs to the clinic.

Authors:  Peter Savas; Roberto Salgado; Carsten Denkert; Christos Sotiriou; Phillip K Darcy; Mark J Smyth; Sherene Loi
Journal:  Nat Rev Clin Oncol       Date:  2015-12-15       Impact factor: 66.675

8.  Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer.

Authors:  S Chae; K M Kang; H J Kim; E Kang; S Y Park; J H Kim; S H Kim; S W Kim; E K Kim
Journal:  Curr Oncol       Date:  2018-04-30       Impact factor: 3.677

9.  Histological Analysis of γδ T Lymphocytes Infiltrating Human Triple-Negative Breast Carcinomas.

Authors:  Jose Villacorta Hidalgo; Peter Bronsert; Marzenna Orlowska-Volk; Liliana B Díaz; Elmar Stickeler; Martin Werner; Annette Schmitt-Graeff; Gian Kayser; Miroslav Malkovsky; Paul Fisch
Journal:  Front Immunol       Date:  2014-12-10       Impact factor: 7.561

10.  Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials.

Authors:  Vassiliki Kotoula; Kyriakos Chatzopoulos; Sotiris Lakis; Zoi Alexopoulou; Eleni Timotheadou; Flora Zagouri; George Pentheroudakis; Helen Gogas; Eleni Galani; Ioannis Efstratiou; Thomas Zaramboukas; Angelos Koutras; Gerasimos Aravantinos; Epaminontas Samantas; Amanda Psyrri; Helen Kourea; Mattheos Bobos; Pavlos Papakostas; Paris Kosmidis; Dimitrios Pectasides; George Fountzilas
Journal:  Oncotarget       Date:  2016-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.